- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 20,596
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis
- Interventions
- PACE-MS
- Behavioral
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Parkinson's Disease, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Salena Killion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopic Dermatitis
- Interventions
- ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more
- Conditions
- Asthma
- Interventions
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
- Conditions
- Diabetes Mellitus, Type 1, Overweight and Obesity
- Interventions
- Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 19 Years to 30 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Chapel Hill, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 99 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Next-line ibrutinib
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 16
- States / cities
- Duarte, California • La Jolla, California • Stanford, California + 13 more
- Conditions
- Status Asthmaticus
- Interventions
- Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer
- Device
- Lead sponsor
- Akron Children's Hospital
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Venetoclax, Bendamustine, Rituximab
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Urbana, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more
- Conditions
- Sjogren's Syndrome, Keratoconjunctivitis Sicca
- Interventions
- Levocarnitine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Procedure · Drug · Other + 2 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections, Staphylococcal Infections
- Interventions
- Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 4
- States / cities
- San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more
- Conditions
- Type 1 Diabetes, Dawn Phenomenon
- Interventions
- Lantus (glargine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer
- Interventions
- KRAS-variant and microRNA binding site mutation testing
- Genetic
- Lead sponsor
- MiraKind
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2035
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab, Matching Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
- Conditions
- Follicular Lymphoma
- Interventions
- Zevalin, Rituximab
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more
- Conditions
- HIV, Acquired Immunodeficiency Syndrome
- Interventions
- Symptom Management Manual
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 7
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV-infection
- Interventions
- Angiotensin II Infusion
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Vesnarinone
- Drug
- Lead sponsor
- Otsuka America Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- methotrexate, sirolimus, tacrolimus
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Allergic Conjunctivitis
- Interventions
- TL-925, Placebo
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee